Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment.
Sichuan UniversityMay 21 2026 Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment.
In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 , a hormone that causes phosphate loss through the kidneys. Because phosphate is essential for proper bone mineralization, persistent hypophosphatemia can further weaken already fragile bones and worsen long-term disability. Existing treatment with oral phosphate and vitamin D supplements is often difficult to tolerate and frequently fails to restore normal phosphate levels.
Addressing this challenge, a research team was led by Dr. Alison M. Boyce, who is a Pediatric Endocrinologist at the Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, USA. The investigators evaluated whether burosumab, a monoclonal antibody that blocks FGF23 activity, could safely improve phosphate balance and markers of skeletal disease and physical function in patients with fibrous dysplasia.
The phase 2 open-label clinical trial included 12 participants, including seven children and five adults with severe disease burden and hypophosphatemia. Participants received burosumab treatment for 48 weeks, with regular monitoring of phosphate metabolism, bone turnover markers, imaging findings, physical function, and patient-reported outcomes. Their findings were published in Volume 14 of the journal Bone Research on April 27, 2026. At the start of the study, participants showed extensive skeletal involvement and major physical disability.
Many relied on wheelchairs, walkers, or crutches for mobility. Treatment with burosumab successfully restored phosphate levels into the mid-to-upper normal target range in all participants by week 48. The therapy also improved phosphate retention in the kidneys and increased levels of active vitamin D, both essential for healthy bone metabolism. Importantly, alkaline phosphatase, a marker associated with abnormal bone turnover and disease activity, declined substantially during treatment.
The researchers also observed encouraging functional improvements, particularly in pediatric participants. Several children reported reduced pain, less fatigue, and improved physical mobility. Two severely affected children experienced especially dramatic gains. One participant progressed from full-time wheelchair use to independent walking without assistive devices, while another child who had never walked independently was able to walk short distances using a walker after treatment.
Our findings demonstrate that targeting phosphate levels in the mid to upper normal range can be both safe and clinically meaningful for patients with fibrous dysplasia. The mobility improvements observed in some children suggest that earlier correction of phosphate imbalance may help reduce long-term disability.
" Dr. Alison M. Boyce, Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health Safety analyses showed that burosumab was generally well tolerated. Most adverse effects were mild and manageable, including temporary episodes of elevated phosphate levels and minor injection-site reactions. Importantly, detailed PET/CT imaging and lesion biopsies showed no evidence that the treatment accelerated lesion growth or increased abnormal tissue activity, addressing a major concern surrounding therapies targeting FGF23 signaling.
The findings may have important implications beyond fibrous dysplasia. The study supports the idea that maintaining optimal phosphate balance could improve outcomes in other disorders driven by excessive FGF23 activity. The results may also encourage collaborations among endocrinologists, bone disease specialists, rehabilitation experts, and rare disease researchers to develop more targeted approaches for skeletal disorders associated with mineral imbalance. Related Stories"Children with severe fibrous dysplasia often experience progressive mobility loss during critical developmental years," Dr. Boyce explained.
"Seeing some patients regain meaningful movement and independence provides strong motivation to continue advancing therapies that directly address the biological drivers of disease. " In the short term, burosumab may offer patients and families a more effective alternative to traditional phosphate supplementation, potentially improving quality of life and reducing treatment burden.
Over the longer term, the research could help establish targeted biologic therapies as a standard approach for managing rare skeletal diseases associated with phosphate wasting, reducing fractures, deformities, and lifelong disabilities. Overall, the study demonstrates that burosumab safely restores phosphate homeostasis and may substantially improve physical function in patients with fibrous dysplasia. The findings provide important clinical evidence supporting targeted FGF23 inhibition as a promising strategy for reducing skeletal complications and improving long-term outcomes in this rare and debilitating disorder.
Source:Sichuan University Journal reference:de Jong, O., et al. A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia. Bone Research. DOI: 10.1038/s41413-026-00523-7.
Children Therapy Antibody Clinical Trial Craniofacial CT Disability Dysplasia Endocrinologist Fibroblast Fibrous Dysplasia Growth Factor Hormone Hypophosphatemia Imaging Metabolism Monoclonal Antibody Muscle Muscle Wasting Oral Pain Research Scoliosis Supplements Vitamin D
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Four more Italian divers' bodies recovered, operation in third phase for final pair's recoveryThe bodies of two Italian divers have been recovered from a cave in the Maldives, bringing the total death toll to five. The grim discovery on Thursday marked the worst single diving accident ever recorded in the history of the country, shocking the nation.
Read more »
Ensitrelvir cuts household COVID-19 risk when given after exposureEnsitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household contacts when given within 72 hours after symptom onset in the infected index patient. In the phase 3 SCORPIO-PEP trial, COVID-19 occurred in 2.9% of ensitrelvir recipients versus 9.
Read more »
Clyde Gateway to launch Strategic Partner Opportunity for Shawfield siteShawfield Phase 1 will bring forward a significant opportunity for modern, innovation-led industrial space, reinforcing the area’s role as a nationally significant hub for advanced manufacturing, science and technology.
Read more »
A Clean Shipping Crunch Is Looming Amid a Conventional Fuel ShortageNorway’s aggressive offshore shipping emissions rules are exposing how unprepared much of the existing vessel fleet is for the next phase of maritime decarbonization.
Read more »